SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid intense market focus on an upcoming high-profile address and recent geopolitical rhetoric, particularly concerning Greenland and global trade. The community is sharply divided, with many anticipating a quick market rebound while others brace for further downside, linking market direction to these unfolding events. This dynamic fuels significant volatility as participants actively debate the broader implications for the economy.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense discussion, largely influenced by President Trump's remarks at the Davos World Economic Forum and ongoing geopolitical tensions. The community remains deeply divided, with many bears highlighting significant drops and questioning Bitcoin's safe-haven status amidst rising gold prices, while bulls emphasize strong accumulation by institutional players and technical indicators pointing to a potential rebound from leveraged short attacks.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as a major institutional holder has registered its substantial stake for a potential sale, creating significant market buzz. This move has ignited a sharp debate among investors, with some viewing it as a bearish signal after a period of underperformance, while others see an attractive opportunity in this dividend-yielding consumer staple. The broader context includes anticipation of a planned company separation into distinct entities, which many believe could unlock value despite ongoing competitive pressures in the food sector.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell...

<ul class="summary-bullets"><li>The European study is expected to enroll 40 newly diagnosed AML patients.</li><li>Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.</li><li>SLS stock is on track to end in the red in five of the last seven sessions.</li></ul>SELLAS Life Sciences Group Inc (SLS) stock was in the spotlight after it signed an agreement with IMPACT-AML (Acute Myeloid Leukemia) to expand the clinical development of SLS009, a targeted cancer therapy, into Europe.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has been trending down lately and is on track to end in the red in five of the last seven sessions. It was trading 3.2% lower. Last week, investors booked profits amid dilution concerns after Sellas reported $26.5 million in proceeds from the exercise of common stock warrants, in addition to its estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">IMPACT-AML Tie Up</h2>The IMPACT-AML, a pan-European initiative within the EU Mission Cancer program, will conduct a European clinical study evaluating SLS009, providing SELLAS access to multiple clinical sites and a broader patient population. SELLAS aims to leverage the partnership to accelerate enrollment, expand patient access to SLS009, and maintain cost efficiency, it added.The European study is expected to enroll 40 newly diagnosed AML patients with high-risk features to evaluate SLS009 in combination with azacitidine and venetoclax, medications to treat cancer. Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.<h2 class="st-heading-2">Retail Chatter</h2>Despite the intraday decline, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/SLS_jpg_8c87a5394f.webp" alt="SLS.jpg">One user saw the IMPACT-AML development as a positive for the stock and wondered why bears were still selling.<stembedurl>https://stocktwits.com/insidersruleloosersdrool/message/641795770</stembedurl>Another user said validating SLS009 in both the U.S. and the EU simultaneously makes the drug more attractive to a global buyer like Novartis.<stembedurl>https://stocktwits.com/Cresskill198/message/641779078</stembedurl>SLS shares have shot up 345% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA">IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Equity

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3% - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10.3% Higher - Time to Buy...

<ul class="summary-bullets"><li>On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants.</li><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.</li><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) fell for the fourth straight session on Friday as investors resorted to profit taking amid dilution concerns.Shares of the company traded 13% lower at $3.34 at the time of writing, after <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-breaches-5-dollar-level-after-over-3-years/cmxuTsiR4RS">breaching</a> the $5 threshold for the first time in over three years earlier this week.On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants. This is in addition to the company’s estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed disappointment at the company diluting shares of the company by exercising warrants provided it has “sufficient cash” to carry out ongoing trials. However, they expect the price to be back up by February.<stembedurl>https://www.stocktwits.com/jackobull/message/641370638</stembedurl>Another, however, said that there is no “legitimate reason” to sell the stock. “...we longs know this is short lived. &nbsp;VERY short lived. &nbsp;It will explode upward from this oversold action,” they wrote.<stembedurl>https://www.stocktwits.com/Wut_About_Bob/message/641368167</stembedurl><h2 class="st-heading-2"> What Drove The Recent Rally?</h2>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study, and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou said at the time. The announcement kickstarted a rally that mostly sustained through late December and early January.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at significant potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-pharmaceuticals-stock-rallies-after-hours-on-strong-genetic-disorder-drug-sales-kickstart/cmUbnxGR45Z">KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?

Shares of the company traded 13% lower at $3.34 at the time of writing.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.4% - Here's Why...

<ul class="summary-bullets"><li>Headlines from CES reignited enthusiasm around AI hardware and autonomous tech.</li><li>Despite the dip, retail sentiment on Stocktwits toward SPY and QQQ remained bullish.&nbsp;</li></ul>U.S. stock futures were trading in the red early Tuesday as investors balance AI optimism from CES, while awaiting crucial jobs data later this week.As of 3:50 a.m. ET on Tuesday, Nasdaq 100 futures and S&amp;P 500 futures fell 0.1%, and the Dow futures fell 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid normal message volumes.Trending Stocks To Watch Nvidia (NVDA):&nbsp;At CES, Jensen Huang&nbsp;announced Nvidia’s next-generation AI chips, Vera Rubin, a successor to&nbsp;its Blackwell architecture, which would go on sale in the second half of the year. It is also joining the push to develop self-driving cars, reinforcing its position as a full-stack AI platform company, not just a chipmaker.&nbsp; Tesla (TSLA): CEO Elon Musk downplayed concerns around Nvidia’s newly unveiled Alpamayo autonomous driving AI.&nbsp; Advanced Micro Devices, Inc. (AMD)&nbsp;garnered retail attention on Stocktwits after the chipmaker&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-crashes-ces-2026-with-all-out-offensive-against-nvidia/cmxwVexR4Tb">launched</a> a slew of AI chips for computers, data centers, and gaming at the CES trade show in Las Vegas. Intel (INTC)&nbsp;unveiled its latest laptop processors, the Core Ultra Series 3, which are set to roll out in new computers later this month. Also, keep an eye on Chevron (CVX), Exxon Mobil Corp (XOM), amid political developments in Venezuela. OneStream (OS):&nbsp;HG Capital is reportedly nearing a deal to acquire the financial software firm.&nbsp; Sellas Lifesciences (SLS)&nbsp;is the top trending ticker on Stocktwits at the time of writing.&nbsp; Aeva (AEVA)&nbsp;is on the retail radar after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiny-lidar-player-aeva-stock-rockets-over-25-after-hours-on-nvidia-deal/cmxwXUUR4RV">announcing</a> its 4D LiDAR will be integrated into the Nvidia Drive Hyperion platform. PLTR (Palantir) and&nbsp;RCAT (Red Cat Holdings) are trending. Traders are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/red-cat-roars-back-venezuela-speculation-sends-drone-stock-flying/cmxw13MR4Rs">speculating</a> on increased contract awards for surveillance and drone technology.&nbsp; Zeta Global (ZETA)&nbsp;is gaining traction following the collaboration with OpenAI to enhance its marketing platform. And&nbsp;Alumis (ALMS) is scheduled to report topline Phase 3 data for envudeucitinib in plaque psoriasis before the open, with a conference call at 8:00 a.m. ET.&nbsp; Other noteworthy tickers trending on Stocktwits at the time of writing were Amazon (AMZN), Momentus In (MNTS), Bank of America (BAC), Alibaba (BABA), Paramount Skydance (PSKY), and Apteva Therapeutics (APVO) Other Catalysts To Watch With no significant economic releases due Tuesday, traders are expected to continue tracking CES developments and positioning ahead of key jobs data later this week. Siemens is expected to showcase its Industrial Metaverse, while Lenovo CEO is expected to unveil the “AI for All” strategy today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.


<ul class="summary-bullets"><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia.</li><li>The stock has had a good run since the company said that slower deaths in the GPS trial might imply further clinical benefit.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) garnered retail attention on Monday after it breached the $5 threshold after over three years during the day trading session.The stock closed 15% higher in the regular trading session to close at $5 and traded 2% higher after hours.<h2 class="st-heading-2">Retail Speaks</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A bullish Stocktwits user rejoiced at the new levels.<stembedurl>https://www.stocktwits.com/Duncan74/message/640892449</stembedurl>Another expressed optimism for a buyout of the company for as much as $25 billion.<stembedurl>https://www.stocktwits.com/Mjohns92/message/640889738</stembedurl><h2 class="st-heading-2">What’s Driving The Rally?</h2>SELLAS is currently <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">evaluating</a> Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company said last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled this year and multiplied by about five times in value over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-gains-nbix-shares-drop-on-positive-results-from-genetics-disorder-trial/cmxMxA1R4Rf">CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

SLS Stock Breaches $5 Levels After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Should You Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High - Should You Buy...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Traders are intensely discussing a potential multi-billion dollar acquisition, with many forecasting a deal up to $40 billion for the company's oncology assets.

Sentiments are heavily skewed towards "shorts getting annihilated" as the stock shows resilience and bullish momentum against significant short interest.

The extended duration of the pivotal Phase 3 REGAL trial for GPS is exciting investors, implying strong overall survival outcomes that could revolutionize AML treatment.

Alongside GPS, investors are highlighting SLS-009 as a key secondary asset, anticipating its "First Patient Dosed" PR to significantly boost valuation.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLSSELLAS Life Sciences Group Inc